FR941103-1-00011 FR941103-1-00004 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Parts 54, 312, 314, 320, 330, 601, 807, 812, 814, and 860 [Docket No. 93N&hyph;0445] Financial Disclosure by Clinical Investigators; Correction AGENCY : Food and Drug Administration, HHS. ACTION : Proposed rule; correction. SUMMARY : The Food and Drug Administration (FDA) is correcting a proposed rule that appeared in the Federal Register of September 22, 1994 (59 FR 48708). The document proposed to require that the sponsor of any drug, biological product, or device submit certain information concerning the compensation to, and financial interests of, any clinical investigator conducting clinical studies to determine whether that product meets the marketing requirements specified by the agency. The document was published with an error. This document corrects that error. DATES : Written comments on or before December 21, 1994. The agency is proposing that any final rule that may issue based on this proposed rule become effective 6 months after the date of its publication in the Federal Register . FOR FURTHER INFORMATION CONTACT : John S. Ensign, Office of Health Affairs (HFY&hyph;22), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20852, 301&hyph;443&hyph;1382. In FR Doc. 94&hyph;23414, appearing on page 48708 in the Federal Register of Thursday, September 22, 1994, the following correction is made: ยง54.4 [Corrected] On page 48717, in ยง54.4 Disclosure requirements , in the first column, in paragraph (a), in the last line, the phrase ``(a)(2) of this section'' is corrected to read ``(a)(3) of this section.'' Dated: October 28, 1994. William K. Hubbard, Interim Deputy Commissioner for Policy. [FR Doc. 94&hyph;27316; Filed 11&hyph;2&hyph;94; 8:45 am] BILLING CODE 4160&hyph;01&hyph;F
